Jazz Pharmaceuticals is proud to support the Diffuse Midline Glioma (DMG) Roundtable on August 26th, 2026

The End Brain Cancer Initiative will be hosting an internal Patient and Healthcare Professional insights Diffuse Midline Glioma (DMG) Roundtable on August 26th, 2026 @11AM featuring leading experts, researchers, advocates, and members of the patient community to discuss the latest treatment advances, clinical trials, and emerging research.

Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.

LEARN MORE ABOUT JAZZ PHARMA

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614

DONATE

EBCI In The News

Patient Stories

Patient Support Services

Patient Resource Center